Maladie de Parkinson : Servier et Oncodesign annoncent la sélection d’un candidat préclinique
Initiée en mars 2019, cette collaboration de Recherche et Développement porte sur la découverte d’inhibiteurs de la kinase LRRK2 issus de la plateforme Nanocyclix®, propriété d’Oncodesign, et sur leur action comme agents thérapeutiques potentiels contre la maladie de Parkinson.
Josselin Caradec, Directeur de programmes Découverte, Responsable du laboratoire in vitro 21 février 2019 – 17h
The use of immunotherapies in oncology has drastically changed the way of treating cancer, providing innovative and efficient therapeutic solutions. Currently, tremendous R&D efforts are done in immuno-oncology to discover new targets and develop new drugs. In that context, the use of relevant and robust assays to predict therapeutic efficiencies has become a key for drug discovery programs. Oncodesign develops a broad range of solutions to support your drug discovery projects in immuno-oncology. We can provide solutions on a stand alone basis or through an integrated drug discovery package – from hit identification to candidate selection. Based on human immune material for in vitro/ex vivo phenotypic assays and on advanced preclinical models – syngeneic or humanized – for in vivo assays, our scientists help you to assess your compound efficiency in routine or customized assays.
Key learning objectives
How Oncodesign can help you to support your drug discovery project at each step of your pre-clinical development.
Vitro/Vivo assays developed by Oncodesign for routine assessment of molecules.
Tailored-made solutions: Case studies
About our speaker Josselin Caradec
Dr Caradec obtained his PhD in Biology in the Oncology field. He joined Oncodesign in 2015 as a Director of Discovery Programs to develop kinase inhibitors up to candidate. He now also heads the in vitro laboratory of Dijon facility and leads preclinical (vitro/vivo) projects for clients in immune-oncology.
18 rue Jean Mazen - FR - 21000 Dijon Tél.+33 380 788 260